State Street SPDR S&P Pharmaceuticals ETF
XPH
76 hedge funds and large institutions have $271M invested in State Street SPDR S&P Pharmaceuticals ETF in 2015 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 18 increasing their positions, 33 reducing their positions, and 13 closing their positions.
8.82% more ownership
Funds ownership: 31.61% → 40.43% (+8.8%)
4% more capital invested
Capital invested by funds: $261M → $271M (+$9.56M)
0% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 13
1% less funds holding
Funds holding: 77 → 76 (-1)
37% less call options, than puts
Call options by funds: $520K | Put options by funds: $824K
45% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 33
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$25.8M |
| 2 |
PVH
Psagot Value Holdings
Tel Aviv,
Israel
|
+$12.2M |
| 3 |
KHLMVGHM
Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet
Tel Aviv,
Israel
|
+$5.48M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$5.08M |
| 5 |
LPL Financial
San Diego,
California
|
+$3.91M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$19.6M |
| 2 |
MG
Mather Group
Chicago,
Illinois
|
-$13.8M |
| 3 |
HF
Hoxton Financial
Shepherdstown,
West Virginia
|
-$8.27M |
| 4 |
Citigroup
New York
|
-$5.21M |
| 5 |
SI
Stephens Inc
Little Rock,
Arkansas
|
-$4.6M |
XPH Hedge Fund Activity: Q4 2015 in Review
76 of the 3,824 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Pharmaceuticals ETF (XPH) for Q4 2015, worth a combined $271M — up 3.7% from $261M a quarter earlier.
Fund positioning in XPH was balanced in Q4 2015: 13 funds opened new positions, 13 closed out, 18 added to existing stakes and 33 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $25.8M. The largest seller was Susquehanna International Group, cutting an estimated $19.6M.
- 76 institutional investors held State Street SPDR S&P Pharmaceuticals ETF (XPH) as of Q4 2015, down from 77 in Q3 2015.
- Funds reported $271M of State Street SPDR S&P Pharmaceuticals ETF stock for Q4 2015, up 3.7% quarter-over-quarter.
- 13 funds opened new State Street SPDR S&P Pharmaceuticals ETF positions in Q4 2015 and 13 closed out, a net change of 0 holders.
- The largest State Street SPDR S&P Pharmaceuticals ETF buyer in Q4 2015 was Goldman Sachs, an estimated $25.8M added.
- The largest State Street SPDR S&P Pharmaceuticals ETF seller in Q4 2015 was Susquehanna International Group, an estimated $19.6M sold.
Based on aggregated 13F filings for Q4 2015.